What does LifeCell International do?

LifeCell International Private Limited is India's largest umbilical cord blood stem cell banking company. It collects, processes, and stores cord blood stem cells from newborns for potential future therapeutic use. The company also offers community stem cell banking and has expanded into tissue banking and regenerative medicine services.

How many stem cell samples has LifeCell stored?

LifeCell has stored over 400,000 stem cell samples from newborns, making it the largest private cord blood bank in India by volume of stored units.

When was LifeCell International incorporated?

LifeCell International Private Limited was incorporated in 2004 in Tamil Nadu (CIN: U85196TN2004PTC053577), making it a 20-year-old company that pioneered private cord blood banking in India.

Is LifeCell International listed on any stock exchange?

No, LifeCell International is an unlisted private limited company. Its shares are available only in the unlisted/OTC pre-IPO market with ISIN INE903K01016.

What are the charges for cord blood banking with LifeCell?

LifeCell offers enrollment packages typically ranging from approximately ₹50,000 to ₹1,50,000 for cord blood collection and initial storage, with annual renewal fees of approximately ₹3,000-5,000 per year for ongoing storage.

What is the ISIN of LifeCell International?

The ISIN of LifeCell International Private Limited is INE903K01016.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for LifeCell International Private Limited?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell LifeCell International Private Limited shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

LifeCell International Private Limited Unlisted Share Price | Buy LifeCell International Private Limited Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

LifeCell International Private Limited Unlisted Share Price | Buy LifeCell International Private Limited Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

LifeCell International Private Limited is India's dominant stem cell banking company with a two-decade track record and a large, growing base of stored stem cell samples generating predictable recurring revenue. Its combination of market leadership, brand trust, and diversifying service portfolio makes it one of the most credible unlisted healthcare companies in India. A potential future IPO could be a significant catalyst for valuation discovery.

Pros

India's largest cord blood stem cell bank by stored units, with over 400,000 stem cell samples banked — a dominant market leader with significant network effects
First-mover advantage in India's stem cell banking industry since 2004, creating 20+ years of brand trust among parents and gynecologists
Highly recurring revenue model: annual storage fees from existing clients create a stable, predictable income stream independent of new enrollment volumes
Strong scientific advisory board and partnerships with leading Indian hospitals and gynecologists providing a robust referral network
Expanding into adjacent areas including tissue banking, community cord blood banking, and regenerative medicine — diversifying the revenue base beyond newborn stem cell banking

Cons

Unlisted company with limited financial transparency, restricting independent investor due diligence
Stem cell banking is a discretionary purchase for parents, making enrollment sensitive to economic downturns and consumer confidence
Growing competition from players like Cord Life, Cryoviva, and Babycord is intensifying pricing pressure on enrollment packages
Public awareness of the medical utility of stored cord blood remains limited in India, constraining addressable market penetration
Regulatory environment for stem cell therapies and banking in India continues to evolve, creating potential compliance risks

Business Segments

Private Cord Blood Banking

Collection, processing, and cryogenic storage of umbilical cord blood stem cells at birth for exclusive family use in future medical treatments. Clients pay an enrollment fee plus annual storage fees.

Community Stem Cell Banking

Shared/public cord blood banking model where donated cord blood is stored and made available to matched patients in need of stem cell transplants — a socially impactful model building India's national stem cell registry.

Tissue Banking & Regenerative Medicine

Storage of other birth tissues (placenta, cord tissue) and expansion into regenerative medicine applications including skin tissue banking for burn treatment and musculoskeletal tissue banking.

Diagnostic & Allied Services

Ancillary services including genetic testing, newborn screening, and maternal health diagnostics offered as complementary products to stem cell banking clients.

Revenue Model

LifeCell generates revenue through a two-part model: upfront enrollment fees paid by parents at the time of cord blood collection (one-time revenue), and annual storage/renewal fees paid by existing clients for ongoing cryogenic storage of stem cells (recurring revenue). The large installed base of 400,000+ stored samples provides a highly predictable recurring revenue stream that compounds as new enrollments add to the base.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds13

Growth Plans

India's rapidly growing middle class and health-conscious parenting culture increasing cord blood banking adoption rates

Advances in stem cell therapy expanding the clinical indications for stored cord blood, increasing perceived value

Community banking program creating a national stem cell registry and improving access to transplant-grade stem cells

Expansion into genetic testing and newborn screening as high-growth allied healthcare services

Recent Developments

Expanded Regenerative Medicine Services

LifeCell expanded its regenerative medicine offerings including advanced tissue banking services and clinical utility programs to drive awareness of stem cell therapy applications among hospitals and physicians.

2023-06

Community Banking Growth

LifeCell's community cord blood banking program continued to grow its registry of publicly available stem cell samples, strengthening its position in the national stem cell transplant ecosystem.

2023-10

Market Leadership Reinforced

LifeCell maintained its position as India's largest cord blood bank with 400,000+ stored samples, continuing to partner with leading maternity hospitals across India to drive new enrollments.

2024-03

Comparable Companies

CompanyTypeTickerMkt Cap

Cryo-Cell InternationalListedCCEL (NASDAQ)~$50 million

Cryo-Cell InternationalListed

CCEL (NASDAQ) · ~$50 million

Frequently Asked Questions

About LifeCell International Private Limited

LifeCell International Private Limited is India's leading stem cell banking and biotech company, incorporated on 28 June 2004 under CIN U85196TN2004PTC053577 and headquartered at No. 26, Vandalur-Kelambakkam Main Road, Keelakottaiyur Village, Kancheepuram District, Chennai, Tamil Nadu 600048. The company is registered with the Registrar of Companies, Chennai and operates as a private limited company. LifeCell pioneered umbilical cord blood and tissue stem cell banking in India, offering parents the option to preserve their newborn's stem cells at birth for potential future therapeutic use. The company processes and stores cord blood, cord tissue (Wharton's jelly), placenta-derived cells, and other birth-associated biological materials — collectively covering the broadest range of newborn stem cell preservation options available in India. With over 500,000 stem cell samples banked, LifeCell manages India's largest private stem cell repository. Beyond stem cell banking, LifeCell has evolved into a diversified healthcare company offering diagnostic testing services, prenatal genetic testing, non-invasive prenatal testing (NIPT), carrier screening, and expanded newborn screening programs. This diversification strategy positions LifeCell as a comprehensive preventive healthcare partner through the pregnancy and neonatal journey — with each touchpoint from conception through infancy addressed by the company's service portfolio. The company's financial trajectory has been exceptional: revenue for FY2024-25 reached Rs. 855 crore, representing a 146% CAGR on a one-year basis. FY2023-24 also showed 59.54% growth. Revenue in USD terms reached approximately USD 193.9 million in FY2025. With 1,210 employees as of August 2025, LifeCell has scaled into a substantial mid-cap healthcare enterprise. The authorized capital stands at Rs. 132.46 crore against paid-up capital of Rs. 19.35 crore. Board members include Sunny Sharma, Sumona Chakraborty, Abhayakumar Deepak, and Abhaya Mayur. LifeCell has partnered with global stem cell organizations and maintains accreditations from AABB (American Association of Blood Banks) and other international quality bodies — credentials that are critical for a company entrusted with long-term biological sample custody.

Key Milestones

Common questions about unlisted shares

How do I buy LifeCell International Private Limited unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

Risk factors & red flagsInvestment risks and items flagged from public filings10

Fraud / GovernanceLow

Cord blood banking penetration in India remains below 2% of annual births — while this represents growth potential, limited awareness and affordability constrain near-term enrollment growth

Source: Media Reports / Public Records

Industry / CompetitionLow

Growing competition from Cord Life International, Cryoviva India, Babycord, and emerging players is intensifying price competition on enrollment packages

Source: AlphaHub Research

Regulatory / LegalLow

India's regulatory framework for stem cell banking and therapeutic applications is evolving; any restrictive regulations could impact the business model

Source: Regulatory Filings

Fraud / GovernanceLow

The actual probability of using privately stored cord blood for treatment remains statistically very low (estimated 1 in 20,000 chance), which could lead to consumer skepticism or regulatory pushback

Source: Media Reports / Public Records

Fraud / GovernanceLow

Unlisted private limited company status means investors face significant illiquidity with no readily available secondary market for share transactions

Source: Media Reports / Public Records

Market Penetration Risk

Cord blood banking penetration in India remains below 2% of annual births — while this represents growth potential, limited awareness and affordability constrain near-term enrollment growth

Competitive Risk

Growing competition from Cord Life International, Cryoviva India, Babycord, and emerging players is intensifying price competition on enrollment packages

Regulatory Risk

India's regulatory framework for stem cell banking and therapeutic applications is evolving; any restrictive regulations could impact the business model

Scientific Utility Risk

The actual probability of using privately stored cord blood for treatment remains statistically very low (estimated 1 in 20,000 chance), which could lead to consumer skepticism or regulatory pushback

Liquidity Risk

Unlisted private limited company status means investors face significant illiquidity with no readily available secondary market for share transactions

LifeCell International Private Limited

How settlement works

Get price alerts for LifeCell International Private Limited

Discuss LifeCell International Private Limited

Other ways to invest